Literature DB >> 31585024

Positional effects of premature termination codons on the biochemical and biophysical properties of CFTR.

Jiunn-Tyng Yeh1,2, Tzyh-Chang Hwang1,2,3.   

Abstract

KEY POINTS: Biochemical and biophysical characterizations of three nonsense mutations of cystic fibrosis transmembrane conductance regulator (CFTR) associated with a severe form of cystic fibrosis (CF) reveal the importance and heterogenous effects of the position of the premature termination codon (PTC) on the CFTR protein function. Electrophysiological studies of W1282X-CFTR, whose PTC is closer to the C-terminus of CFTR, suggest the presence of both C-terminus truncated CFTR proteins that are poorly functional and read-through, full-length products. For G542X- and E60X-CFTR, the only mechanism capable of generating functional proteins is the read-through, but the outcome of read-through products is highly variable depending on the interplay between the missense mutation caused by the read-through and the structural context of the protein. Pharmacological studies of these three PTCs with various CFTR modulators suggest position-dependent therapeutic strategies for these disease-inflicting mutations. ABSTRACT: About one-third of genetic diseases and cancers are caused by the introduction of premature termination codons (PTCs). In theory, the location of the PTC in a gene determines the alternative mechanisms of translation, including premature cessation or reinitiation of translation, and read-through, resulting in differential effects on protein integrity. In this study, we used CFTR as a model system to investigate the positional effect of the PTC because of its well-understood structure-function relationship and pathophysiology. The characterization of three PTC mutations, E60X-, G542X- and W1282X-CFTR revealed heterogenous effects of these PTCs on CFTR function. The W1282X mutation results in both C-terminus truncated and read-through proteins that are partially or fully functional. In contrast, only the read-through protein is functional with E60X- and G542X-CFTR, although abundant N-terminus truncated proteins due to reinitiation of translation were detected in E60X-CFTR. Single-channel studies of the read-through proteins of E60X- and G542X-CFTR demonstrated that both mutations have a single-channel amplitude similar to wild type (WT), and good responses to high-affinity ATP analogues, suggesting intact ion permeation pathways and nucleotide binding domains (NBDs), albeit with reduced open probability (Po ). The comparison of the Po of these mutations with the proposed missense mutations revealed potential identities of the read-through products. Importantly, a majority of the functional protein studied responds to CFTR modulators like GLPG1837 and Lumacaftor. These results not only expand current understanding of the molecular (patho)physiology of CFTR, but also infer therapeutic strategies for different PTC mutations at large.
© 2019 The Authors. The Journal of Physiology © 2019 The Physiological Society.

Entities:  

Keywords:  ABC transporters; cystic fibrosis; nonsense mutations; translational read-through

Mesh:

Substances:

Year:  2019        PMID: 31585024      PMCID: PMC8087279          DOI: 10.1113/JP278418

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  85 in total

1.  CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains.

Authors:  Paola Vergani; Steve W Lockless; Angus C Nairn; David C Gadsby
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

2.  Molecular Structure of the Human CFTR Ion Channel.

Authors:  Fangyu Liu; Zhe Zhang; László Csanády; David C Gadsby; Jue Chen
Journal:  Cell       Date:  2017-03-23       Impact factor: 41.582

3.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

4.  Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.

Authors:  Kang-Yang Jih; Tzyh-Chang Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

5.  Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations.

Authors:  M Howard; R A Frizzell; D M Bedwell
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

6.  Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.

Authors:  Eitan Kerem; Samit Hirawat; Shoshana Armoni; Yasmin Yaakov; David Shoseyov; Michael Cohen; Malka Nissim-Rafinia; Hannah Blau; Joseph Rivlin; Micha Aviram; Gary L Elfring; Valerie J Northcutt; Langdon L Miller; Batsheva Kerem; Michael Wilschanski
Journal:  Lancet       Date:  2008-08-20       Impact factor: 79.321

7.  Modulation of CFTR gating by permeant ions.

Authors:  Han-I Yeh; Jiunn-Tyng Yeh; Tzyh-Chang Hwang
Journal:  J Gen Physiol       Date:  2014-12-15       Impact factor: 4.086

8.  Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency.

Authors:  D N Sheppard; L S Ostedgaard; M C Winter; M J Welsh
Journal:  EMBO J       Date:  1995-03-01       Impact factor: 11.598

9.  Spatial positioning of CFTR's pore-lining residues affirms an asymmetrical contribution of transmembrane segments to the anion permeation pathway.

Authors:  Xiaolong Gao; Tzyh-Chang Hwang
Journal:  J Gen Physiol       Date:  2016-05       Impact factor: 4.086

10.  Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations.

Authors:  Lulu Huang; Audrey Low; Sagar S Damle; Melissa M Keenan; Steven Kuntz; Susan F Murray; Brett P Monia; Shuling Guo
Journal:  Genome Biol       Date:  2018-01-15       Impact factor: 13.583

View more
  5 in total

1.  Pharmacological Responses of the G542X-CFTR to CFTR Modulators.

Authors:  Xinxiu Fang; Jiunn-Tyng Yeh; Tzyh-Chang Hwang
Journal:  Front Mol Biosci       Date:  2022-06-24

2.  Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G.

Authors:  Iris A L Silva; Tereza Doušová; Sofia Ramalho; Raquel Centeio; Luka A Clarke; Violeta Railean; Hugo M Botelho; Andrea Holubová; Iveta Valášková; Jiunn-Tyng Yeh; Tzyh-Chang Hwang; Carlos M Farinha; Karl Kunzelmann; Margarida D Amaral
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-07-28       Impact factor: 5.187

3.  Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing.

Authors:  Steven Erwood; Onofrio Laselva; Teija M I Bily; Reid A Brewer; Alexandra H Rutherford; Christine E Bear; Evgueni A Ivakine
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-12       Impact factor: 6.698

Review 4.  Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.

Authors:  Isabelle Fajac; Isabelle Sermet
Journal:  Cells       Date:  2021-10-19       Impact factor: 6.600

5.  CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway.

Authors:  Edward J Sanderlin; Melissa M Keenan; Martin Mense; Alexey S Revenko; Brett P Monia; Shuling Guo; Lulu Huang
Journal:  Nat Commun       Date:  2022-04-29       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.